Skip to main content
DERM
NASDAQ Life Sciences

Journey Medical Reports Strong FY2025 Results, Reduced Loss, and Increased Cash Amidst Going Concern

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$6.83
Mkt Cap
$227.142M
52W Low
$5.51
52W High
$9.555
Market data snapshot near publication time

summarizeSummary

Journey Medical Corporation announced full-year 2025 financial results, reporting a 10% revenue increase, significantly reduced net loss, and improved cash position, driven by the successful launch of Emrosi™.


check_boxKey Events

  • Strong Revenue Growth

    Total revenues increased 10% to $61.9 million for FY2025, primarily driven by the successful launch of Emrosi™.

  • Reduced Net Loss & Improved Profitability

    Net loss decreased to $11.4 million from $14.7 million, and Adjusted EBITDA significantly improved to $2.9 million from $0.8 million in the prior year.

  • Increased Cash and Working Capital

    The company ended FY2025 with $24.1 million in cash and cash equivalents and $29.4 million in working capital, up from $20.3 million and $13.0 million, respectively, in FY2024.

  • Emrosi™ Driving Growth

    Emrosi™, launched in April 2025, generated $14.7 million in net revenues and achieved expanded payer access to over 100 million commercial lives.


auto_awesomeAnalysis

Journey Medical's full-year 2025 financial results demonstrate significant operational improvements, particularly with a 10% increase in total revenues to $61.9 million and a substantial reduction in net loss from $14.7 million to $11.4 million. The successful launch of Emrosi™ was a key driver, contributing $14.7 million in net revenues. Crucially, the company reported a notable increase in cash and cash equivalents to $24.1 million and a doubling of working capital to $29.4 million. These positive financial developments are highly significant, especially in light of the company's previous "going concern" warning and recent capital-raising efforts (S-3 and ATM program in January 2026). While the going concern language remains in the forward-looking statements, the improved financial health provides a stronger foundation and suggests progress in addressing its liquidity challenges. Investors will likely view these results as a positive step towards long-term stability.

At the time of this filing, DERM was trading at $6.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.1M. The 52-week trading range was $5.51 to $9.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed DERM - Latest Insights

DERM
Apr 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
DERM
Mar 25, 2026, 6:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
DERM
Mar 25, 2026, 5:35 PM EDT
Filing Type: 10-K
Importance Score:
9
DERM
Mar 25, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
DERM
Jan 23, 2026, 4:06 PM EST
Filing Type: 424B3
Importance Score:
8
DERM
Jan 15, 2026, 4:43 PM EST
Filing Type: S-3
Importance Score:
9